Products - Prostate cancer | Topic | NICE

Showing 9 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 January 2025
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
Status:
In development
Programme:
Medical technologies guidance
Expected publication date:
TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC